6-K

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

FORM 6-KREPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2018

Commission File Number: 0-30752

Aeterna Zentaris Inc.

(Translation of registrant’s name into English)

315 Sigma Drive, Suite 302DSummerville, South Carolina, USA 29486 (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.Form 20-F ☒      Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

This report on Form 6-K, including the exhibits hereto, shall be deemed incorporated by reference into the Registrant’s Registration Statement on Form F-3 (File No. 333-216853), its Registration Statements on Form S-8 (File Nos. 333-210561 and 333-200834) and its Registration Statement on Form F-10 (File No. 333-208789) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

DOCUMENTS INDEX

Exhibit	Description
99.1	Material Change Report of the Registrant dated March 5, 2018.

SIGNATURE

Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 5, 2018	AETERNA ZENTARIS INC.
	/s/Michael V. Ward
	Michael V. Ward
	Chief Executive Officer

EX-99.1

Exhibit 99.1

FORM 51-102F3

MATERIAL CHANGE REPORT

Item 1  Name and Address of Company

Aeterna Zentaris Inc. (the “Company”)

c/o Stikeman Elliott LLP

1155 René-Lévesque Blvd. West

41st Floor

Montréal, Québec

H3B 3V2

Item 2  Date of Material Change

March 5, 2018.

Item 3  News Release

On March 5, 2018, the Company issued a news release indicating the material change, which was disseminated on the Globe Newswire news service.

Item 4Summary of Material Change

On March 5, 2018, the Company announced that it had appointed James Clavijo as Chief Financial Officer, effective today.

Item 5.  Full Description of Material Change

On March 5, 2018, the Company announced that it had appointed James Clavijo as Chief Financial Officer, effective today. Before joining the Company, Mr. Clavijo served as Chief Financial Officer at Tri-Source Pharma. Tri-Source is a pharmaceutical company focused on procuring pharmaceutical products facing supply issues and supplying pharmaceutical products to veterinary markets. Prior to serving as Chief Financial Officer of Tri-Source Pharma, Mr. Clavijo also served for seven years as founder of Capital View Partners, a consulting firm providing Chief Financial Officer services, and for five years as the Chief Accounting Officer at Soligenix, a public biopharmaceutical company. Mr. Clavijo received a bachelor’s degree in Chemistry from the University of Florida, a bachelor’s degree in Accounting from the University of Nebraska, and a master’s degree in Accounting from Florida International University.

Item 5.2  Disclosure for Restructuring Transactions

Not applicable.

Item 6  Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7  Omitted Information

Not applicable.

Item 8  Executive Officer

Further information regarding the matter described in this report may be obtained from Michael V. Ward, Chief Executive Officer, at 843-900-3201 or IR@AEZSinc.com.

Item 9  Date of Report

March 5, 2018.